Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 186

1.

Importance of Local Control in Early-Stage Prostate Cancer: Outcomes of Patients With Positive Post-Radiation Therapy Biopsy Results Treated in RTOG 9408.

Krauss DJ, Hu C, Bahary JP, Souhami L, Gore EM, Chafe SM, Leibenhaut MH, Narayan S, Torres-Roca J, Michalski J, Zeitzer KL, Donavanik V, Sandler H, McGowan DG, Jones CU, Shipley WU.

Int J Radiat Oncol Biol Phys. 2015 Jul 15;92(4):863-73. doi: 10.1016/j.ijrobp.2015.03.017.

2.

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.

Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D.

Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1243-52.

PMID:
11483335
3.

Radiotherapy and short-term androgen deprivation for localized prostate cancer.

Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, Leibenhaut MH, Husain SM, Rotman M, Souhami L, Sandler HM, Shipley WU.

N Engl J Med. 2011 Jul 14;365(2):107-18. doi: 10.1056/NEJMoa1012348.

4.

Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy.

D'Amico AV, Chen MH, Renshaw AA, Loffredo B, Kantoff PW.

J Clin Oncol. 2008 Jun 20;26(18):2979-83. doi: 10.1200/JCO.2007.15.9699.

PMID:
18565884
5.

Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.

Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB.

Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1520-9.

PMID:
15050332
6.

Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir.

Alexander AS, Mydin A, Jones SO, Christie J, Lim JT, Truong PT, Ludgate CM.

Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):e713-9. doi: 10.1016/j.ijrobp.2010.11.068.

PMID:
21277102
7.

A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902.

Rosenthal SA, Hunt D, Sartor AO, Pienta KJ, Gomella L, Grignon D, Rajan R, Kerlin KJ, Jones CU, Dobelbower M, Shipley WU, Zeitzer K, Hamstra DA, Donavanik V, Rotman M, Hartford AC, Michalski J, Seider M, Kim H, Kuban DA, Moughan J, Sandler H.

Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):294-302. doi: 10.1016/j.ijrobp.2015.05.024.

8.

Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy.

Liauw SL, Stadler WM, Correa D, Weichselbaum RR, Jani AB.

Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):125-30. doi: 10.1016/j.ijrobp.2009.04.074.

9.

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.

Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, Atkinson C, Tai KH, Christie D, Kenny L, Turner S, Gogna NK, Diamond T, Delahunt B, Oldmeadow C, Attia J, Steigler A.

Lancet Oncol. 2014 Sep;15(10):1076-89. doi: 10.1016/S1470-2045(14)70328-6.

PMID:
25130995
10.

Percentage of positive biopsy cores: a better risk stratification model for prostate cancer?

Huang J, Vicini FA, Williams SG, Ye H, McGrath S, Ghilezan M, Krauss D, Martinez AA, Kestin LL.

Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1141-8. doi: 10.1016/j.ijrobp.2011.09.043.

PMID:
22099043
11.

Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes?

King CR, Presti JC Jr, Gill H, Brooks J, Hancock SL.

Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):341-7.

PMID:
15145146
12.

Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group.

Nguyen PL, Chen MH, Beard CJ, Suh WW, Renshaw AA, Loffredo M, McMahon E, Kantoff PW, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1046-52. doi: 10.1016/j.ijrobp.2009.06.038.

PMID:
19864082
13.
14.

Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer.

D'Amico AV, Schultz D, Loffredo M, Dugal R, Hurwitz M, Kaplan I, Beard CJ, Renshaw AA, Kantoff PW.

JAMA. 2000 Sep 13;284(10):1280-3.

PMID:
10979115
15.

Prognostic importance of Gleason 7 disease among patients treated with external beam radiation therapy for prostate cancer: results of a detailed biopsy core analysis.

Spratt DE, Zumsteg Z, Ghadjar P, Pangasa M, Pei X, Fine SW, Yamada Y, Kollmeier M, Zelefsky MJ.

Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1254-61. doi: 10.1016/j.ijrobp.2012.10.013.

PMID:
23182392
16.
17.

External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes.

Akimoto T, Kitamoto Y, Saito J, Harashima K, Nakano T, Ito K, Yamamoto T, Kurokawa K, Yamanaka H, Takahashi M, Mitsuhashi N, Niibe H.

Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):372-9.

PMID:
15145150
18.

Lymph node-positive prostate cancer: evaluation of the results of the combination of androgen deprivation therapy and radiation therapy.

Buskirk SJ, Pisansky TM, Atkinson EJ, Schild SE, O'Brien PC, Wolfe JT, Zincke H.

Mayo Clin Proc. 2001 Jul;76(7):702-6.

PMID:
11444402
19.

Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.

Jang JW, Hwang WT, Guzzo TJ, Wein AJ, Haas NB, Both S, Vapiwala N.

Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1493-9. doi: 10.1016/j.ijrobp.2011.10.047.

PMID:
22401922
Items per page

Supplemental Content

Support Center